PHARM Pharming Group N.V.

1.207USD1.099 EUR · AMS-1.52%Mkt Cap: 867.85M USDP/E: 37.18

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. Th…

Institutional holders10 on file

Key Statistics

Company
Market Cap867.85M USD
Enterprise Value756.21M USD
Revenue (TTM)386.75M USD
Gross Profit330.63M USD
Net Income (TTM)2.85M USD
Revenue/Share0.52 USD
Last Price1.207 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees407
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINNL0010391025
Valuation
P/E (Trailing)37.18
P/E (Forward)33.23
PEG—
EV/EBITDA12.07
EV/Revenue1.96
P/S2.04
P/B2.94
EPS (TTM)0.03 USD
EPS (Forward)0.03 USD
52W Range
0.901628% of range1.998
52W High1.998 USD
52W Low0.9016 USD
Profitability
Gross Margin87.90%
Oper. Margin12.78%
EBITDA Margin14.74%
Profit Margin0.76%
ROE1.03%
ROA0.57%
ROIC4.88%
ROCE5.44%
Growth
Revenue Growth20.80%
Earnings Growth74.90%
Cash Flow & Leverage
Operating CF54.71M USD
CapEx (TTM)755.00K USD
FCF Margin10.98%
FCF Yield4.89%
Net Debt-75.05M USD
Net Debt/EBITDA-1.32
Net Debt/FCF-1.77
Balance Sheet
Debt/Equity0.42
Current Ratio3.23
Quick Ratio2.65
Book Value/Sh0.38 USD
Cash/Share0.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMar 5, 2013
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2.467 USD
Upside (mean)+104.3%
Target Range2.131 USD – 2.744 USD
2.131+104.3% to mean2.744
# Analysts4
Ownership
Shares Out.707.78M
Float673.18M
Insiders0.95%
Institutions22.24%
Technical
SMA 501.074 (+12.5%)
SMA 2001.269 (-4.8%)
Beta0.05
S&P 52W Chg12.00%
Avg Vol (30d)10.47M
Avg Vol (10d)9.95M
Technical Indicators
RSI (14)59.8
MACD0.0468
MACD Signal0.0540
MACD Hist.-0.0072
BB Upper1.314 USD
BB Middle1.225 USD
BB Lower1.135 USD
BB Width14.55%
ATR (14)0.0425 USD
Vol Ratio (20d)0.58x

About Pharming Group (AMS: PHARM)

›

Pharming Group (AMS: PHARM) is listed on Euronext Amsterdam, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 407 employees.

The shares were at 1.099 EUR on 20 November 2026, down 19.7% over 52 weeks. Its 52-week range is 0.8202 EUR to 1.818 EUR: the price is 39.6% below the high and 33.9% above the low.

At a market capitalisation of 789.53M EUR, it trades at 37.2 times trailing earnings and 33.2 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 11% for PHARM.

Pharming Group reports return on equity of 1.0%, an operating margin of 12.8% and revenue up 20.8% year over year.

It holds more cash than debt, a net cash position of 75.05M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 2.244 EUR is 104.3% above the current price. The next earnings report is expected on 11 March 2027.